Welcome to our dedicated page for MAXC news (Ticker: MAXC), a resource for investors and traders seeking the latest updates and insights on MAXC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MAXC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MAXC's position in the market.
MaxCyte, a leader in cell engineering technology, announced the public filing of a registration statement on Form S-1 with the SEC for a proposed dual-listing and public offering on Nasdaq. The filing includes unaudited financial data for Q1 2021, showing a 30% revenue growth (excluding milestone revenues) to $6.5 million. The company also completed a $55.3 million private placement and signed a strategic license with Myeloid Therapeutics. Additionally, Ron Holtz resigned from the board to comply with Nasdaq practices while continuing as CAO.
MaxCyte, Inc. announced the public filing of a registration statement with the SEC for a proposed dual listing of its common stock on the Nasdaq under the symbol 'MXCT'. The company plans to conduct a public offering of shares in the U.S. The share count and price range for the Offering are yet to be determined, with the commencement dependent on SEC review. MaxCyte's stock will continue to trade on the AIM market of the London Stock Exchange. This move aims to broaden its market presence and attract U.S. investors while enhancing its liquidity.
